Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...

The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...

US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Robert F. Kennedy Jr., who's nominated to become the next health secretary, asked the federal government to revoke its ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...

We recently compiled a list of the 10 Firms Drop on Bearish Statements, Disappointing Earnings. In this article, we are going ...

Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.

The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.

Moderna said on Monday it achieved $3 billion to $3.1 billion in product sales in 2024, and reduced cash operating costs by ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.